Literature DB >> 15946586

The cancer anorexia/weight loss syndrome: therapeutic challenges.

Karin F Giordano1, Aminah Jatoi.   

Abstract

The cancer anorexia/weight loss syndrome is characterized by loss of weight, loss of appetite, overall decline in quality of life, and shortened survival in patients with advanced incurable cancer. It is highly prevalent. To date, treatment options that have been firmly established with good scientific evidence are limited to progestational agents and corticosteroids, both of which have been demonstrated to improve appetite but have otherwise failed to have a favorable impact on some of the other aspects of this syndrome. As the mechanisms behind this syndrome are further elucidated, more effective therapeutic strategies will likely emerge.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15946586     DOI: 10.1007/s11912-005-0050-9

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  32 in total

1.  Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy.

Authors:  Paula Ravasco; Isabel Monteiro-Grillo; Pedro Marques Vidal; Maria Ermelinda Camilo
Journal:  J Clin Oncol       Date:  2005-01-31       Impact factor: 44.544

2.  A pilot study of the Functional Living Index-Cancer (FLIC) Scale for the assessment of quality of life for metastatic lung cancer patients. An Eastern Cooperative Oncology Group study.

Authors:  D M Finkelstein; B R Cassileth; P D Bonomi; J C Ruckdeschel; E Z Ezdinli; J M Wolter
Journal:  Am J Clin Oncol       Date:  1988-12       Impact factor: 2.339

3.  Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer.

Authors:  C L Loprinzi; R M Goldberg; J Q Su; J A Mailliard; S A Kuross; A W Maksymiuk; J W Kugler; J R Jett; C Ghosh; D M Pfeifle
Journal:  J Clin Oncol       Date:  1994-06       Impact factor: 44.544

4.  An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort.

Authors:  Aminah Jatoi; Kendrith Rowland; Charles L Loprinzi; Jeff A Sloan; Shaker R Dakhil; Neil MacDonald; Bruno Gagnon; Paul J Novotny; James A Mailliard; Teresita I L Bushey; Suresh Nair; Brad Christensen
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

5.  Symptoms and prognosis in advanced cancer.

Authors:  Declan Walsh; Lisa Rybicki; Kristine A Nelson; Sinead Donnelly
Journal:  Support Care Cancer       Date:  2002-01-08       Impact factor: 3.603

6.  Phase III evaluation of 4 doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia.

Authors:  C L Loprinzi; A M Bernath; D J Schaid; J A Malliard; L M Athmann; J C Michalak; L K Tschetter; A K Hatfield; R F Morton
Journal:  Oncology       Date:  1994-10       Impact factor: 2.935

7.  Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity.

Authors:  M A Socinski; C Zhang; J E Herndon; R O Dillman; G Clamon; E Vokes; W Akerley; J Crawford; M C Perry; S L Seagren; M R Green
Journal:  Ann Oncol       Date:  2004-07       Impact factor: 32.976

8.  Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group.

Authors:  C L Loprinzi; J A Laurie; H S Wieand; J E Krook; P J Novotny; J W Kugler; J Bartel; M Law; M Bateman; N E Klatt
Journal:  J Clin Oncol       Date:  1994-03       Impact factor: 44.544

9.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

Authors:  W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

10.  Evaluation of nutritional status in advanced metastatic cancer.

Authors:  N Sarhill; F Mahmoud; D Walsh; K A Nelson; S Komurcu; M Davis; S LeGrand; O Abdullah; L Rybicki
Journal:  Support Care Cancer       Date:  2003-08-15       Impact factor: 3.603

View more
  7 in total

1.  [A case report of the difficulty treating an endstage oncologic ENT patient with parenteral nutrition].

Authors:  Ulrike Uxa-Benold; Ralph Simanek; Annette Henry; Dietmar Weixler; Klaus Geissler
Journal:  Wien Med Wochenschr       Date:  2014-04-29

Review 2.  Evolving classification systems for cancer cachexia: ready for clinical practice?

Authors:  David Blum; Aurelius Omlin; Ken Fearon; Vickie Baracos; Lukas Radbruch; Stein Kaasa; Florian Strasser
Journal:  Support Care Cancer       Date:  2010-03       Impact factor: 3.603

3.  Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides.

Authors:  Christoph Otto; Ulrike Kaemmerer; Bertram Illert; Bettina Muehling; Nadja Pfetzer; Rainer Wittig; Hans Ullrich Voelker; Arnulf Thiede; Johannes F Coy
Journal:  BMC Cancer       Date:  2008-04-30       Impact factor: 4.430

Review 4.  Cancer cachexia: lessons from Drosophila.

Authors:  Ying Liu; Pedro Saavedra; Norbert Perrimon
Journal:  Dis Model Mech       Date:  2022-03-23       Impact factor: 5.758

5.  Estimation of Cachexia among Cancer Patients Based on Four Definitions.

Authors:  Kathleen M Fox; John M Brooks; Shravanthi R Gandra; Richard Markus; Chiun-Fang Chiou
Journal:  J Oncol       Date:  2009-07-01       Impact factor: 4.375

6.  Pentoxifylline treatment in patients with cancer cachexia: A double-blind, randomized, placebo-controlled clinical trial.

Authors:  Valiollah Mehrzad; Rohollah Afshar; Mojtaba Akbari
Journal:  Adv Biomed Res       Date:  2016-03-22

7.  Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials.

Authors:  Shailesh M Advani; Pragati G Advani; Helena M VonVille; Syed H Jafri
Journal:  BMC Cancer       Date:  2018-11-27       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.